These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 10373718)

  • 21. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes.
    Braunwald E; Maseri A; Armstrong PW; Califf RM; Gibler WB; Hamm CW; Simoons ML; Van de Werf F
    Eur Heart J; 1998 Apr; 19 Suppl D():D22-30. PubMed ID: 9597519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.
    Lincoff AM; Califf RM; Topol EJ
    J Am Coll Cardiol; 2000 Apr; 35(5):1103-15. PubMed ID: 10758948
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glycoprotein IIb/IIIa inhibitors: current indications and future prospects.
    Reginelli JP; Topol EJ
    Am J Med; 2000 Aug; 109(3):252-4. PubMed ID: 10974193
    [No Abstract]   [Full Text] [Related]  

  • 24. The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: a cost-effectiveness analysis.
    Glaser R; Glick HA; Herrmann HC; Kimmel SE
    J Am Coll Cardiol; 2006 Feb; 47(3):529-37. PubMed ID: 16458131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Roe MT; Sapp SK; Lincoff AM
    Cleve Clin J Med; 2000 Feb; 67(2):131-40. PubMed ID: 10680279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GP IIb/IIIa inhibitors: an evidence-based approach to their use.
    Med Manag Netw; 1999 Mar; 7(3):5-9. PubMed ID: 10346546
    [No Abstract]   [Full Text] [Related]  

  • 27. The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
    Sabatine MS; Jang IK
    Am J Med; 2000 Aug; 109(3):224-37. PubMed ID: 10974186
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic issues in glycoprotein IIb/IIIa receptor therapy.
    Hillegass WB; Newman AR; Raco DL
    Am Heart J; 1999 Jul; 138(1 Pt 2):S24-32. PubMed ID: 10385788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of glycoprotein IIb/IIIa-receptor inhibitors during percutaneous coronary intervention.
    Cheng JW
    Am J Health Syst Pharm; 2002 Nov; 59(21 Suppl 7):S5-14. PubMed ID: 12434710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.
    Boersma E; Akkerhuis KM; Théroux P; Califf RM; Topol EJ; Simoons ML
    Circulation; 1999 Nov; 100(20):2045-8. PubMed ID: 10562258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications.
    Lincoff AM; Califf RM; Anderson KM; Weisman HF; Aguirre FV; Kleiman NS; Harrington RA; Topol EJ
    J Am Coll Cardiol; 1997 Jul; 30(1):149-56. PubMed ID: 9207636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Glycoprotein IIb/IIIa platelet blockers in acute myocardial infarct treated with primary coronary angioplasty].
    Kala P; Poloczek M; Bocek O; Jerábek P; Neugebauer P; Kosová J; Semrád B
    Vnitr Lek; 2002 Aug; 48(8):736-41. PubMed ID: 12425204
    [TBL] [Abstract][Full Text] [Related]  

  • 33. More evidence for a beneficial effect of platelet glycoprotein IIb/IIIa-blockade during coronary interventions. Latest results from the EPILOG and CAPTURE trials.
    van de Werf F
    Eur Heart J; 1996 Mar; 17(3):325-6. PubMed ID: 8737200
    [No Abstract]   [Full Text] [Related]  

  • 34. Platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease.
    Lefkovits J; Topol EJ
    Curr Opin Cardiol; 1995 Jul; 10(4):420-6. PubMed ID: 7549085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention.
    Kereiakes DJ; Broderick TM; Roth EM; Whang D; Shimshak T; Runyon JP; Hattemer C; Schneider J; Lacock P; Mueller M; Abbottsmith CW
    Am J Cardiol; 1999 Aug; 84(4):391-5. PubMed ID: 10468074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Are stenting and glycoprotein IIb/IIIa blockade of good value in primary percutaneous coronary intervention?
    Cole JH; Weintraub WS
    Circulation; 2003 Dec; 108(23):2831-3. PubMed ID: 14662689
    [No Abstract]   [Full Text] [Related]  

  • 37. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
    Lincoff AM; Tcheng JE; Califf RM; Kereiakes DJ; Kelly TA; Timmis GC; Kleiman NS; Booth JE; Balog C; Cabot CF; Anderson KM; Weisman HF; Topol EJ
    Circulation; 1999 Apr; 99(15):1951-8. PubMed ID: 10208997
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
    Hobbach HP; Schuster P
    Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
    Subbarao VD; Phillips J; Stouffer GA
    Am J Med Sci; 1999 Aug; 318(2):107-14. PubMed ID: 10452570
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.
    Topol EJ; Ferguson JJ; Weisman HF; Tcheng JE; Ellis SG; Kleiman NS; Ivanhoe RJ; Wang AL; Miller DP; Anderson KM; Califf RM
    JAMA; 1997 Aug; 278(6):479-84. PubMed ID: 9256222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.